Related Experiment Videos
[Biologic response modifiers in the treatment of solid tumors]
F Tagliaferri1, G Lucandri, F Stipa
1V Clinica chirurgica, Università La Sapienza, Roma.
Recenti Progressi in Medicina
|June 1, 1991
Summary
Biologic Response Modifiers show promise in treating cancers like renal cell carcinoma and melanoma. Further research into cancer immunology and optimized therapeutic strategies is needed to improve clinical efficacy and limit adverse effects.
Area of Science:
- Oncology
- Immunology
Context:
- Review of prospective studies from 1990 on Biologic Response Modifiers (BRMs) in cancer treatment.
- Focus on neoplasms like renal cell carcinoma and melanoma with proven sensitivity to BRMs.
- Inclusion criteria specified route and rate of response (complete and partial).
Purpose:
- To evaluate the clinical applications and efficacy of Biologic Response Modifiers in Oncology.
- To identify factors contributing to the controversial clinical efficacy of BRMs.
- To highlight the need for further research in cancer immunology.
Summary:
- Clinical efficacy of Biologic Response Modifiers remains controversial, potentially due to cancer immunogenicity, varied administration routes, and lack of predictive markers.
- Studies reviewed focused on specific cancers and response metrics.
- In-depth understanding of cancer immunology is crucial for advancing immunotherapy.
Impact:
- Suggests that improved therapeutic strategies and reduced adverse effects are necessary for wider immunotherapy adoption.
- Emphasizes the need for more research to overcome current limitations in BRM treatment.
- Highlights the potential of BRMs in specific oncological conditions.